Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew D Hellmann

Showing results (41-50 of 172) with videos related to

Pageof 18
Sort By:
Plos One|August 4, 2017
Expression of PD-L1 and other immunotherapeutic targets in thymic epithelial tumorsKathryn C Arbour, Jarushka Naidoo, Keith E Steele, et al.
Journal of the National Cancer Institute|January 2, 2017
Thinking Critically About Classifying Adverse Events: Incidence of Pancreatitis in Patients Treated With Nivolumab + IpilimumabClaire F Friedman, Varina Clark, Andrew V Raikhel, et al.
Journal for Immunotherapy of Cancer|February 11, 2021
Success and failure of additional immune modulators in steroid-refractory/resistant pneumonitis related to immune checkpoint blockadeJason Beattie, Hira Rizvi, Paige Fuentes, et al.
Nature|November 14, 2017
A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapyMarta Łuksza, Nadeem Riaz, Vladimir Makarov, et al.
Advances in Radiation Oncology|September 12, 2018
Safety of combining thoracic radiation therapy with concurrent versus sequential immune checkpoint inhibitionDonata von Reibnitz, Jamie E Chaft, Abraham J Wu, et al.
Nature|May 18, 2017
Chromatin states define tumour-specific T cell dysfunction and reprogrammingMary Philip, Lauren Fairchild, Liping Sun, et al.
ESMO Open|June 27, 2018
30 Immunotherapy in advanced NSCLC-from the 'tsunami' of therapeutic knowledge to a clinical practice algorithm: results from an international expert panel meeting of the Italian Association of Thoracic Oncology (AIOT)Filippo de Marinis, Fortunato Ciardiello, Paul Baas, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 20, 2023
Clinical Benefit From Immunotherapy in Patients With SCLC Is Associated With Tumor Capacity for Antigen PresentationCharles M Rudin, David Balli, W Victoria Lai, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 9, 2021
Treatment Outcomes and Clinical Characteristics of Patients with KRAS-G12C-Mutant Non-Small Cell Lung CancerKathryn C Arbour, Hira Rizvi, Andrew J Plodkowski, et al.
Journal for Immunotherapy of Cancer|March 14, 2023
Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with chemotherapyNaiyer Rizvi, Foluso O Ademuyiwa, Z Alexander Cao, et al.
Pageof 18

Showing results (41-50 of 172) with videos related to

Sort By:
Pageof 18
Plos One|August 4, 2017
Expression of PD-L1 and other immunotherapeutic targets in thymic epithelial tumorsKathryn C Arbour, Jarushka Naidoo, Keith E Steele, et al.
Journal of the National Cancer Institute|January 2, 2017
Thinking Critically About Classifying Adverse Events: Incidence of Pancreatitis in Patients Treated With Nivolumab + IpilimumabClaire F Friedman, Varina Clark, Andrew V Raikhel, et al.
Journal for Immunotherapy of Cancer|February 11, 2021
Success and failure of additional immune modulators in steroid-refractory/resistant pneumonitis related to immune checkpoint blockadeJason Beattie, Hira Rizvi, Paige Fuentes, et al.
Nature|November 14, 2017
A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapyMarta Łuksza, Nadeem Riaz, Vladimir Makarov, et al.
Advances in Radiation Oncology|September 12, 2018
Safety of combining thoracic radiation therapy with concurrent versus sequential immune checkpoint inhibitionDonata von Reibnitz, Jamie E Chaft, Abraham J Wu, et al.
Nature|May 18, 2017
Chromatin states define tumour-specific T cell dysfunction and reprogrammingMary Philip, Lauren Fairchild, Liping Sun, et al.
ESMO Open|June 27, 2018
30 Immunotherapy in advanced NSCLC-from the 'tsunami' of therapeutic knowledge to a clinical practice algorithm: results from an international expert panel meeting of the Italian Association of Thoracic Oncology (AIOT)Filippo de Marinis, Fortunato Ciardiello, Paul Baas, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 20, 2023
Clinical Benefit From Immunotherapy in Patients With SCLC Is Associated With Tumor Capacity for Antigen PresentationCharles M Rudin, David Balli, W Victoria Lai, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 9, 2021
Treatment Outcomes and Clinical Characteristics of Patients with KRAS-G12C-Mutant Non-Small Cell Lung CancerKathryn C Arbour, Hira Rizvi, Andrew J Plodkowski, et al.
Journal for Immunotherapy of Cancer|March 14, 2023
Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with chemotherapyNaiyer Rizvi, Foluso O Ademuyiwa, Z Alexander Cao, et al.
Pageof 18